Precision BioSciences
Durham, North Carolina, United States · Biotechnology, Genetics, Health Care
Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Pre
Key facts
- Headquarters
- Durham, North Carolina, United States
- Employees
- 106
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (DTIL)
- Website
- precisionbiosciences.com
- Company page
Recent activity at Precision BioSciences
- : SEC 8-K (7.01): On August 24, 2026, Precision BioSciences, Inc. announced the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial, which is evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). This significant milestone took place at Arkansas Children’s Hospital, marking an important step in the clinical development of their gene therapy aimed at treating this genetic condition. The press release detailing this announcement is included as Exhibit 99.1 in the filing. This event highlights Precision BioSciences' ongoing commitment to advancing therapeutic options for patients with DMD, and is pivotal in the trajectory of their clinical program.
- : Precision BioSciences Promotes Alex Kelly to Chief Operating Officer
- : Precision BioSciences receives $7.5M from TG Therapeutics for achieving a clinical milestone with azer-cel, enhancing its cash runway.
- : Precision BioSciences Secures Funding through Underwriting Agreement
- : SEC 8-K (1.01): On November 10, 2025, Precision BioSciences, Inc. entered into a material definitive underwriting agreement with Guggenheim Securities, LLC for the offering, issuance, and sale of 10,815,000 shares of its common stock at a combined price of $6.14, along with one-half warrants to purchase up to an additional 5,407,500 shares. Additionally, the agreement includes pre-funded warrants to purchase up to 1,400,000 shares for certain investors. This strategic move is intended to strengthen the company's capital position and support its ongoing business initiatives. The transaction's completion and terms signify a crucial fundraising step for Precision BioSciences.
- : Precision BioSciences Launches PBGENE-HBV to Investigate Safety and Antiviral Activity in Chronic Hepatitis B Patients.
- : Precision BioSciences Appoints Cindy Atwell as Chief Development and Business Officer and Cassie Gorsuch, PhD as Chief Scientific Officer
- : Precision BioSciences Announces Presentation at ESGCT Congress Highlighting ARCUS Gene Editing Platform
- : Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
- : Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
Precision BioSciences funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Funding Round | $7.5M |
| Nov 2025 | Funding Round | $66.4M |
| Feb 2024 | Venture | $7.5M |
| Mar 2019 | Venture | $39.6M |
| Jun 2018 | Venture | $88.1M |
Leadership
- Michael Amoroso, President & CEO
- Naresh Tanna, Chief of Staff to the CEO / Commercial Head
- Buki Acipd, HRBP Director
- Shalini Sharp, Director
- Tony Yao, Director
- Robert Adelman, Director
- Derek Jantz, Executive Officer, Director
- Matthew Kane, Executive Officer, Director
- Michael Amoroso, Executive Officer, Director
- Alex Kelly, Chief Operating Officer
- Alex Kelly, Chief Financial Officer
- Zach Stanley, Process Development
Verified email and direct lines for Precision BioSciences’s decision-makers are on Fundz. See plans
Employee benefit plans
Precision BioSciences files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Precision BioSciences in the news
- Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 - investor.precisionbiosciences.com (May 27, 2026)
- Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones - Business Wire (Jul 27, 2026)
- Precision BioSciences Appoints Michael Amoroso Chief Executive Officer - investor.precisionbiosciences.com (Sep 27, 2021)
- Precision BioSciences Appoints Melinda Brown to Board of Directors - investor.precisionbiosciences.com (May 31, 2022)
- Precision BioSciences Appoints Alex Kelly as Chief Financial Officer - investor.precisionbiosciences.com (May 27, 2021)
- Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer - investor.precisionbiosciences.com (Oct 14, 2020)
- Precision BioSciences Appoints Juli Blanche as Chief People Officer - investor.precisionbiosciences.com (May 23, 2022)
- Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors - investor.precisionbiosciences.com (Apr 12, 2021)
Companies similar to Precision BioSciences
- VolitionRx · Biotechnology, Genetics, Health Care, Therapeutics
- Passage Bio · Biotechnology, Genetics, Health Care, Therapeutics
- uniQure · Biotechnology, Genetics, Health Care, Therapeutics
- Franklin Biolabs · Biotechnology, Genetics, Health Care, Therapeutics
- Applied StemCell · Biotechnology, Genetics, Health Care, Therapeutics
About Precision BioSciences: questions and answers
What does Precision BioSciences do?
Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Pre
Where is Precision BioSciences headquartered?
Precision BioSciences is headquartered in Durham, North Carolina, United States.
How many employees does Precision BioSciences have?
Precision BioSciences has about 106 employees.
Has Precision BioSciences raised funding?
Yes. Fundz has recorded 5 funding events for Precision BioSciences. The most recent, Funding Round of $7.5M, was in Mar 2026.
Who leads Precision BioSciences?
Michael Amoroso is a President & CEO at Precision BioSciences.
What is the latest news on Precision BioSciences?
On Aug 24, 2026, SEC 8-K (7.01): On August 24, 2026, Precision BioSciences, Inc. announced the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial, which is evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). This significant milestone took place at Arkansas Children’s
Is Precision BioSciences a public company?
Yes. Precision BioSciences is publicly traded under the ticker DTIL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy